COPY

DOCKET NO. L0461.70066US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.:	6,794,131 B1
Issue Date:	September 21, 2004
Patentee:	Lethe, et al.
Serial No:	09/341,829
Confirmation No:	5643
Filing Date	October 18, 1999
For:	LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 3rd day of November, 2004.

June Watson

June Watson

Mail Stop Certificate of Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following document(s):

- [X] **Request for Entrance of Certificate of Correction Under 35 U.S.C. §254 & §255**
- [X] **Certificate of Correction - Form PTO-1050**
- [X] **Copy of pertinent page from U.S. Patent No. US 6,794,131 B1**
- [X] **Return Receipt Postcard**

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned collect at (617) 646-8000, Boston, Massachusetts.

No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Lethe, et al., Patentee

By: John R. Van Amsterdam

John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. L0461.70066US00
Date: November 5, 2004
xNDD

DOCKET NO. L0461.70066US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.:	6,794,131 B1
Issue Date:	September 21, 2004
Patentee:	Lethe, et al.
Serial No:	09/341,829
Confirmation No:	5643
Filing Date	October 18, 1999
For:	LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 3rd day of November, 2004.

June Watson

Mail Stop Certificate of Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following document(s):

- [X] **Request for Entrance of Certificate of Correction Under 35 U.S.C. §254 & §255**
- [X] **Certificate of Correction - Form PTO-1050**
- [X] **Copy of pertinent page from U.S. Patent No. US 6,794,131 B1**
- [X] **Return Receipt Postcard**

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned collect at (617) 646-8000, Boston, Massachusetts.

No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Lethe, et al., Patentee

By: John R. Van Amsterdam

John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. L0461.70066US00
Date: November 5, 2004
xNDD

DOCKET NO. L0461.70066US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.:	6,794,131 B1
Issue Date:	September 21, 2004
Patentee:	Lethe, et al.
Serial No:	09/341,829
Confirmation No:	5643
Filing Date	October 18, 1999
For:	LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 5th day of November, 2004.

June Watson

Mail Stop Certificate of Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR ENTRANCE OF CERTIFICATE OF CORRECTION
UNDER 35 U.S.C. §254 and §255

Sir/Madam:

Patentee respectfully requests the correction of an error in the printing of the above-captioned patent. Specifically, claim 4 has a typographical error made by the Patent Office. Please correct as follows: In column 45, line 59, "922" should be replaced with --992--.

Patentee points out that the correction requested does not involve change in the patent that constitutes new matter or would require reexamination, and therefore, respectfully request that a certificate of correction be issued. Patentee encloses a copy of the issued patent with the error highlighted. Since the error was made by the Patent Office, it is respectfully submitted that no fee is due. However, if the Examiner deems a fee necessary, the fee may be charged to Deposit Account No. 23/2825. Should any questions arise concerning the foregoing, please contact the undersigned at the telephone number listed below.

For the reasons stated above, Patentee respectfully requests entrance of the enclosed Certificate of Correction.

Respectfully submitted,
Lethe, et al., Patentee

By: John R. Van Amsterdam

John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. L0461.70066US00
Date: November 5, 2004
xNDD

840314.1

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : US 6,794,131 B1

DATED : September 21, 2004

INVENTORS : Lethe, et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims:

Claim 4,

In Column 45, line 59, delete "922" and replace with --992--.

MAILING ADDRESS OF SENDER:

John R. Van Amsterdam
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211

PATENT NO. US 6,794,131 B1

NOV 12 2004

Form PTO-1050

-continued

gccatgcagg ccgaaggc 18

<210> SEQ ID NO 11
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

ctggccactc gtgctggga 19

<210> SEQ ID NO 12
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

gcaggatgga aggtgccc 18

<210> SEQ ID NO 13
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13

ccccaccgct tcccgtg 17

<210> SEQ ID NO 14
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

ggctgaatgg atgctgcaga 20

What is claimed is:

1. An isolated nucleic acid molecule selected from the group consisting of

(a) a nucleic acid molecule which comprises the nucleotide sequence set forth as SEQ ID NO:4 and which encodes SEQ ID NO:5,

(b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and

(c) full-length complete complements of (a) and (b).

2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule consists of the nucleotide sequence of SEQ ID NO:4.

3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the coding region of the nucleotide sequence of SEQ ID NO:4.

4. An isolated nucleic acid molecule selected from the group consisting of:

(a) a fragment of nucleotides 1-993 of SEQ ID NO:4 consisting of contiguous nucleotides between 15 and 992 ~~922~~ in length, said fragments found only in SEQ ID NO:4, and

(b) full length complete complement of "(a)".

5. An expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter.

6. An isolated host cell transformed or transfected with the expression vector of claim 5.

7. The isolated host cell of claim 6, wherein the isolated host cell expresses an HLA molecule.

8. A method for diagnosing cancer, comprising:

contacting a biological sample isolated from a subject with a probe that hybridizes under high stringency hybridization conditions to SEQ ID NO:4, wherein the probe consists of the isolated nucleic acid molecule of claim 1a or claim 1c, wherein the high stringency hybridization conditions are hybridization at 65° C. in hybridization buffer (3.5×SSC, 0.02% Ficoll, 0.02% polyvinyl pyrolidone, 0.02% Bovine Serum Albumin, 25 mM NaH_2PO_4 (pH 7), 0.5% SDS, 2 mM EDTA), wherein SSC is 0.15 M sodium chloride/0.015 M sodium citrate, pH 7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid and washing at 2×SSC at room temperature and then at 0.1× SSC/0.1×SDS at 65° C., and

determining the binding of the probe to a nucleic acid molecule in the sample to determine expression of the nucleic acid molecule, wherein the expression of the nucleic acid molecule is diagnostic for the presence of cancer in the subject.

9. A method for diagnosing cancer comprising

detecting the presence of (a) SEQ ID NO:4, (b) a fragment of SEQ ID NO:4 consisting of between 22 and 992 contiguous nucleotides in length, wherein the fragment excludes nucleic acid molecules which consist only of fragments of SEQ ID NO:8, or (c) full-length complete complements of (a) or (b) by nucleic acid amplification.

10. The method of claim 9, wherein the nucleic acid amplification is reverse transcribed polymerase chain reaction (RT-PCR).

* * * * *